Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Echinocandin B is a cyclic lipopeptide fermentation product naturally produced by the fungus *Aspergillus nidulans*. It serves as a critical pharmaceutical intermediate in the synthesis of semi-synthetic echinocandin antifungal agents, most notably anidulafungin. Developed and manufactured by Shandong Freda Biotech, echinocandin B functions by inhibiting 1,3-beta-glucan synthase, an enzyme essential for the synthesis of beta-glucan in the fungal cell wall. The disruption of cell wall integrity leads to osmotic instability and fungal cell death. While echinocandin B itself possesses antifungal properties, its primary commercial utility is as a starting material for the production of more stable and potent clinical antifungal drugs used to treat invasive candidiasis and aspergillosis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on echinocandin B.